One day old mangrove rivulus (Rivulus ocellatus marmoratus) were exposed to 9 mg/l diethylnitrosamine (DEN) for 6 weeks, kept in water without DEN for an additional 18-20 months, then necropsied. Oncogene expression was detected by immunohistochemical staining of freeze-dried cryofixed livers. Positive controls for immunohistochemistry included tumors grown by injecting athymic nude mice with cell lines having known oncogene expression. Livers from 15 DEN-exposed fish contained 178 altered foci and neoplasms; 48% of these lesions over-expressed Ras, Myc, Fos, p53 or epidermal growth factor receptor (EGFR). Raf overexpression was not detected. Myc overexpression was positively correlated (P < 0.05) with smaller hepatocyte size in both hepatocellular neoplasms and in altered foci. Increased EGFR expression occurred primarily in inflamed lesions. Increased Ras expression in hepatocellular neoplasms was correlated with anaplasia, gamma-glutamyltranspeptidase activity and lesions that contained mixed acinar and trabecular profiles. Accumulation of p53 occurred more often in neoplasms than in altered foci and correlated with unusual cytoplasmic vacuoles. In hepatocellular neoplasms, Fos overexpression was correlated with increased cell diameter, nuclear pleomorphism, and enlarged nucleoli. Only 1/14 biliary neoplasms overexpressed an oncoprotein (Myc). None of the changes in oncoprotein expression were correlated with cell proliferation (bromodeoxyuridine staining). Although several of the correlations found in mangrove rivulus also occur in mammals, the general relevance of some of our findings can be determined only after they are confirmed in other species.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/carcin/15.9.1993 | DOI Listing |
Appl Biochem Biotechnol
January 2025
Computational Biology Lab, Department of Genetic Engineering, School of Bioengineering, SRM Institute of Science and Technology, SRM Nagar, Kattankulathur, 603203, Tamil Nadu, India.
JAK1, a key regulator of multiple oncogenic pathways, is a sought-out target, and its expression in immune cells and tumour-infiltrating lymphocytes (TILs) is associated with a favorable prognosis in breast cancer. JAK1 activates IL-6 via ERBB2 receptor tyrosine kinase signalling and promotes metastatic cancer and STAT3 activation in breast cancer cells. Hence, targeting JAK1 in breast cancer is being explored as a potential therapeutic strategy.
View Article and Find Full Text PDFDiscov Oncol
January 2025
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People's Republic of China.
Monotherapy with anti-programmed cell death protein 1 (PD-1) monoclonal antibody has been approved for the treatment of advanced non-small cell lung cancer with positive programmed cell death-ligand 1 (PD-L1) expression and oncogene wild type, which revealed survival benefit compared with chemotherapy. Nevertheless, certain patients develop rapid progression on anti-PD-1 inhibitor monotherapy. This novel pattern is called hyperprogressive disease (HPD), and the underlying mechanism and molecular characteristics still leaves not clear.
View Article and Find Full Text PDFJ Biomed Mater Res A
January 2025
Department of Biomedical Engineering, University of Delaware, Newark, Delaware, USA.
Triple-negative breast cancer (TNBC) is infamous for its aggressive phenotype and poorer prognosis when compared to other breast cancer subtypes. One factor contributing to this poor prognosis is that TNBC lacks expression of the receptors that available hormonal or molecular-oriented therapies attack. New treatments that exploit biological targets specific to TNBC are desperately needed to improve patient outcomes.
View Article and Find Full Text PDFPrev Nutr Food Sci
December 2024
Department of Culinary Arts & Hotel Food Service, Yeonsung University, Gyeonggi 14011, Korea.
The inhibitory effect of L. on adipocyte differentiation can be enhanced by lactic acid bacteria (LAB) fermentation. In this study, we assessed the cellulose resolution, L.
View Article and Find Full Text PDFBioact Mater
March 2025
School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, Shandong, 264005, China.
Despite significant advances in targeted therapies and immunotherapies, non-small cell lung cancer (NSCLC) continues to present a global health challenge, with a modest five-year survival rate of 28 %, largely due to the emergence of treatment-resistant and metastatic tumors. In response, we synthesized a novel bioactive compound, ethyl 6-chlorocoumarin-3-carboxylyl L-theanine (TClC), which significantly inhibited NSCLC growth, epithelial mesenchymal transition (EMT), migration, and invasion and tumor growth and metastasis without inducing toxicity. TClC disrupts autocrine loops that promote tumor progression, particularly in stem-like CD133-positive NSCLC (CD133+ LC) cells, which are pivotal in tumor metastasis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!